Search the Newsreel

Core Laboratories Inc. (CLB) stock price, news, quote and history

Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture

Core Laboratories (NYSE:CLB) recently reported weak earnings, which did not significantly impact its stock price. An analysis suggests that the company's profit was boosted by US$7.1 million in unusual items in the last year, raising concerns that future profits may be weaker without these …

Core Laboratories (CLB) Q2 2026 Earnings Call Transcript

Core Laboratories (CLB) reported Q2 2026 earnings, showing 2% sequential revenue growth driven by increased demand for completion products, despite ongoing geopolitical conflicts in the Middle East and Russia/Ukraine impacting its Reservoir Description segment. The company highlighted improved Production Enhancement operating margins due to …

Dimensional Fund Advisors LP Increases Stock Position in Core Laboratories Inc. $CLB

Dimensional Fund Advisors LP has increased its stake in Core Laboratories Inc. (NYSE:CLB) by 10.0% in the first quarter, now owning 1,352,329 shares valued at $22,705,000. Other institutional investors like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., American Century Companies Inc., and Quantbot Technologies LP …

Core Laboratories Inc (CLB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Core Laboratories Inc (CLB), noting its current earnings forecast score of 6.00 and an average price target of $14.00 based on three analysts. It highlights an expected revenue of $131.33M for the next quarter and an anticipated …

Core Laboratories Inc. (CLB) Stock Price, News, Quote & History

This article provides a comprehensive overview of Core Laboratories Inc. (CLB), including its current stock price, recent news like its dividend announcement, and detailed financial data. It covers company performance metrics, analyst ratings, and an in-depth profile of its operations in the oil and …

BlackRock (CLB holder) discloses 8.3% beneficial stake in Core Laboratories Inc

BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.3% beneficial ownership in Core Laboratories Inc (CLB). This stake amounts to 3,811,390 shares, with BlackRock holding sole voting power over 3,703,577 shares and sole dispositive power over all 3,811,390 shares. No single BlackRock …

Core Laboratories (NYSE: CLB) CEO purchases 5,000 shares in open-market trade

Core Laboratories Inc. (NYSE: CLB) Chairman and CEO Bruno Lawrence purchased 5,000 shares of the company's common stock on July 31, 2026, at a price of $10.78 per share in an open-market transaction. This purchase increased his direct holdings to 262,438 shares. The Form …

Core Laboratories (NYSE:CLB) CEO Lawrence Bruno Buys 5,000 Shares

Core Laboratories CEO Lawrence Bruno recently purchased 5,000 shares of the company's stock for $53,900, increasing his total ownership to 262,438 shares. This insider buying comes as the company reported Q2 EPS of $0.11, surpassing estimates, though revenue declined by 4.3% year-over-year. Core Laboratories …

CORE LAB REPORTS SECOND QUARTER 2026 RESULTS

Core Laboratories Inc. reported its second quarter 2026 results, with revenue of $124.6 million, a 2% sequential increase, and GAAP EPS of $0.13. The company highlighted sequential improvements despite geopolitical conflicts impacting its Reservoir Description segment. Core Lab also announced a quarterly dividend and …

Core Laboratories (NYSE:CLB) Rating Increased to Hold at Wall Street Zen

Core Laboratories Q2 Earnings Beat Estimates, Decline Y/Y

Core Laboratories (CLB) reported Q2 2026 adjusted earnings of 11 cents per share, surpassing estimates but declining year-over-year due to underperformance in the Reservoir Description segment and increased costs. Revenues of $124.6 million missed estimates and decreased from the previous year, attributed to geopolitical …

Q2 2026 Core Laboratories Inc Earnings Call Transcript

Core Laboratories Inc (CLB) reported mixed results for Q2 2026, with production enhancement revenue increasing by 15% sequentially and 5% year-over-year due to international reservoir characterization projects and proprietary perforating technology. However, reservoir description revenue declined by 4% sequentially and 9% year-over-year, impacted by …

Core Laboratories Earnings Call Signals Gradual Recovery

Core Laboratories reported Q2 2026 revenue of $124.6 million, a 2% increase sequentially but a 4% decrease year-over-year, impacted by Middle East and Russia-Ukraine conflicts. The company's CEO, Larry Bruno, highlighted investments in new technologies and improving conditions outside conflict zones, particularly in Production …

Core Laboratories Inc. /DE/ Q2 2026: Revenue $124.6M, EPS $0.12— 10-Q Summary

Core Laboratories Inc. /DE/ reported its Q2 2026 financial results with revenue of $124.6 million, marking a 4% year-over-year decrease from $130.2 million in Q2 2025. Diluted earnings per share dropped to $0.12 from $0.23 in the prior year, primarily due to weaker international …

Core Laboratories: Q2 Earnings Snapshot

This article provides a brief earnings snapshot for Core Laboratories' Q2, but contains no actual financial details or article content beyond the headline. The body of the article is empty, indicating a placeholder or an article that failed to load content.

Core Laboratories Inc. (NYSE:CLB) Declares $0.01 Quarterly Dividend

Core Laboratories Inc. (NYSE:CLB) announced a quarterly dividend of $0.01 per share, payable on August 31st. The company reported second-quarter EPS of $0.11, exceeding analyst estimates, but revenue declined year-over-year. Despite the earnings beat, the stock traded down 7.7% near its 52-week low, influenced …

Core Lab Q2 earnings miss analyst estimates

Core Laboratories Inc. (NYSE:CLB) reported Q2 results that missed analyst expectations, with adjusted EPS of $0.13 against a $0.30 consensus. Revenue was $124.6 million, showing sequential improvement but a year-over-year decline, largely due to geopolitical conflicts impacting its Reservoir Description segment. Despite the miss, …

Core Laboratories Inc (CLB) Institutional Confidence

Core Laboratories Inc (CLB) has an institutional shareholding score of 10.00, placing it first in its industry. The institutional shareholding proportion is 111.85%, reflecting a quarterly decrease of 9.75%. Bill Nygren of OAKMX is the largest institutional shareholder, holding 15.76M shares, which represents 28.60% …

Core Laboratories (CLB) Q2 Earnings Surpass Estimates

Core Laboratories (CLB) reported Q2 earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, marking a 37.50% surprise. Despite the earnings beat, the company's revenues of $124.61 million missed estimates and were down from the previous year. The stock …

Core Laboratories (NYSE:CLB) Releases Q3 2026 Earnings Guidance

Core Laboratories (NYSE:CLB) has released its Q3 2026 earnings guidance, projecting EPS between $0.12 and $0.20 and revenue between $128.5 million and $135.5 million, generally aligning with analyst consensus. The stock fell sharply to $9.87, near its 12-month low, on high trading volume, reflecting …

Core Laboratories Inc. Approves Cash Dividend, Payable on August 31, 2026

Core Laboratories Inc. announced on July 29, 2026, that its Board of Directors approved a cash dividend of $0.01 per share of common stock. The dividend is scheduled to be paid on August 31, 2026, to shareholders who are on record by August 10, …

Core Laboratories (NYSE:CLB) Issues Earnings Results

Core Laboratories Inc (CLB) Financial Health: Profitability & Balance Sheet Analysis

Core Laboratories Inc (CLB) currently holds a financial score of 6.00, placing it 138th out of 160 in the Professional & Commercial Services industry, indicating stable financial health with average operating efficiency. The company recently reported a quarterly revenue of $121.80M, down 1.45% year-over-year, …

Core Laboratories (NYSE: CLB) posts Q2 profit, buybacks and Q3 guidance

Core Laboratories (NYSE: CLB) reported Q2 2026 revenue of $124.6 million, up 2.3% sequentially but down 4.3% year-over-year, with diluted EPS of $0.13. The company repurchased 214,712 shares for $2.7 million and declared a quarterly dividend of $0.01 per share. For Q3 2026, Core …

Core Laboratories Inc (CLB) Cash Flow

This article provides a comprehensive overview of Core Laboratories Inc.'s (CLB) cash flow statement, including operating, investing, and financing cash flows, presented in a quarterly and annual format. It details various components such as net income, capital expenditures, and debt transactions, enabling evaluation of …

Core Laboratories Inc (CLB) Income Statement

This article provides the quarterly and annual income statements for Core Laboratories Inc (CLB), detailing its financial performance and operational efficiency. It presents data for various financial metrics over several years and quarters, including total revenue, operating expenses, and net income, alongside year-over-year percentage …

CLB|Core Laboratories Inc|Price:11.670|Chg%:-0.120

This article provides a detailed financial overview of Core Laboratories Inc (CLB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive data dashboard with quarterly and annual financial statements such as income statements, balance sheets, and cash flow statements. …

Core Laboratories Inc (CLB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Core Laboratories Inc (CLB), detailing its price momentum score of 3.60 within the Professional & Commercial Services industry. It highlights the stock's current trading range between a resistance level of 12.44 and a support level of 10.74. …

Core Laboratories Inc (CLB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of Core Laboratories Inc (CLB) revenue by business segment and geographical region. It shows that the company's revenue is primarily driven by service sales, accounting for 75.86% of the total, with product sales making up the remaining 24.14%. …

What's in Store for Core Laboratories Stock in Q2 Earnings?

Core Laboratories (CLB) is scheduled to release its Q2 2026 earnings on July 29, with the Zacks Consensus Estimate projecting a profit of 8 cents per share on revenues of $127.56 million. Despite expected benefits from resilient international projects and an asset-light business model, …

Core Laboratories (NYSE:CLB) Trading Up 5.9% - Here's What Happened

Core Laboratories (NYSE:CLB) saw its stock price increase by 5.9% in mid-day trading on Wednesday, though trading volume was lighter than usual. This rise occurred despite recent downgrades from analysts at Weiss Ratings and Wall Street Zen, both issuing "Sell" ratings, resulting in a …

Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline

Core Laboratories (CLB) is expected to report a year-over-year decline in Q2 earnings and revenues. The company's Earnings ESP (Expected Surprise Prediction) currently stands at +6.67%, suggesting a potential earnings beat, though its Zacks Rank of #4 (Sell) complicates a definitive prediction. Investors are …